Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs

Basit Öğe Kaydı
dc.contributor.authorYurekli, Banu Sarer
dc.contributor.authorKaraca, Burcak
dc.contributor.authorCetinkalp, Sevki
dc.contributor.authorUslu, Ruchan
dc.date.accessioned2019-10-27T20:49:06Z
dc.date.available2019-10-27T20:49:06Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractBreast cancer is the most common malignancy diagnosed among women. According to the new molecular subclassification, basal like and Her-2 positive breast cancers have the worst outcome and these are the ones in which chemotherapy is a must as a part of adjuvant treatment. New treatment options that could be used as an adjuvant maintenance treatment are still being investigated. Insulin hormone is one of the reasons of breast cancer recurrence and death in breast cancer survivors. Targeting insulin as a therapeutic modality in breast cancer could be an option in the adjuvant treatment of breast cancer. It seems that insulin may signal to activate a cascade of proliferative and anti-apoptotic events in the cancer cell. Metformin, an oral anti-diabetic known for 50 years, may also have direct effects on cancer cells. Metformin causes Her-2 suppression via the inhibition of mTOR in breast cancer cells. Thus, we believe that the time has arrived both to target insulin reduction and to alter Her-2 oncogene based molecular pathogenetic steps in breast cancer by using metformin as an adjuvant therapy in breast cancer patients. (C) 2009 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.mehy.2009.05.027en_US
dc.identifier.endpage607en_US
dc.identifier.issn0306-9877
dc.identifier.issue4en_US
dc.identifier.pmid19560877en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage606en_US
dc.identifier.urihttps://doi.org/10.1016/j.mehy.2009.05.027
dc.identifier.urihttps://hdl.handle.net/11454/42814
dc.identifier.volume73en_US
dc.identifier.wosWOS:000270374400041en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofMedical Hypothesesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleIs it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu